← All trials
NCT05605301
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 2, 2022
- Primary completion
- Oct 1, 2023
- Completion date
- Oct 1, 2023
- First posted
- Nov 4, 2022
- Last posted
- Nov 4, 2022
- Enrollment
- 9
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of VirginiaLead sponsor
- University of VirginiaOverall official - principal investigator
- University of VirginiaReponsible party - principal investigator
- University of WisconsinCollaborator
- Epilepsy FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.